
The study investigates the clinical impact of double-dose (4 mg) aflibercept versus standard-dose (2 mg) treatment in neovascular age-related macular degeneration (nAMD). Retrospective analysis of 108 eyes revealed trends toward reduced intraretinal fluid and increased central macular thickness (CMT) reduction in the 4 mg group, including those switching from 2 mg. Remission intervals were longer with 4 mg, with fewer injections needed. However, no significant vision improvements were noted. High-dose aflibercept shows potential for reducing treatment burden in nAMD management, warranting further real-world application.
Like
Save
Share